



## **Bidirectional manipulation of gene expression in adipocytes using CRISPRa and siRNA**

Lundh, Morten; Plucińska, Kaja; Isidor, Marie S.; Petersen, Patricia S.S.; Emanuelli, Brice

*Published in:*  
Molecular Metabolism

*DOI:*  
[10.1016/j.molmet.2017.07.001](https://doi.org/10.1016/j.molmet.2017.07.001)

*Publication date:*  
2017

*Document version*  
Publisher's PDF, also known as Version of record

*Document license:*  
[CC BY-NC-ND](https://creativecommons.org/licenses/by-nc-nd/4.0/)

*Citation for published version (APA):*  
Lundh, M., Plucińska, K., Isidor, M. S., Petersen, P. S. S., & Emanuelli, B. (2017). Bidirectional manipulation of gene expression in adipocytes using CRISPRa and siRNA. *Molecular Metabolism*, 6(10), 1313-1320.  
<https://doi.org/10.1016/j.molmet.2017.07.001>

# Bidirectional manipulation of gene expression in adipocytes using CRISPRa and siRNA



Morten Lundh, Kaja Plucińska, Marie S. Isidor, Patricia S.S. Petersen, Brice Emanuelli\*

## ABSTRACT

**Objective:** Functional investigation of novel gene/protein targets associated with adipocyte differentiation or function heavily relies on efficient and accessible tools to manipulate gene expression in adipocytes *in vitro*. Recent advances in gene-editing technologies such as CRISPR-Cas9 have not only eased gene editing but also greatly facilitated modulation of gene expression without altering the genome. Here, we aimed to develop and validate a competent *in vitro* adipocyte model of controllable functionality as well as multiplexed gene manipulation in adipocytes, using the CRISPRa “SAM” system and siRNAs to simultaneously overexpress and silence selected genes in the same cell populations.

**Methods:** We introduced a stable expression of dCas9-VP64 and MS2-P65, the core components of the CRISPRa SAM system, in mesenchymal C3H/10T1/2 cells through viral delivery and used guide RNAs targeting *Pparγ2*, *Prdm16*, *Zfp423*, or *Ucp1* to control the expression of key genes involved in adipocyte differentiation and function. We additionally co-transfected mature adipocytes with sgRNA plasmids and siRNA to simultaneously up-regulate and silence selected genes. Quantitative gene expression, oxygen consumption, fluorescence-activated cell sorting and immunocytochemistry served as validation proxies in pre- or mature adipocytes.

**Results:** CRISPRa SAM-mediated up-regulation of a key adipogenic gene, *Pparγ2*, was successfully achieved using selected sgRNAs targeting the *Pparγ2* promoter region (i.e. up to  $10^4$  fold); this induction was long lasting and sufficient to promote adipogenesis. Furthermore, co-activation of *Pparγ2* with either *Prdm16* or *Zfp423* transcripts drove distinct thermogenic gene expression patterns associated with increased or decreased oxygen consumption, respectively, mimicking typical characteristics of brite/beige or white cell lineages. Lastly, we demonstrated that up-regulation of endogenous genes in mature adipocytes was also easily and efficiently achieved using CRISPRa SAM, here exemplified by targeted *Ucp1* overexpression (up to  $4 \times 10^3$  fold), and that it was compatible with concomitant gene silencing using siRNA, allowing for bidirectional manipulation of gene expression in the same cell populations.

**Conclusions:** We demonstrate that the CRISPRa SAM system can be easily adopted and used to efficiently manipulate gene expression in pre- and mature adipocytes *in vitro*. Moreover, we describe a novel methodological approach combining the activation of endogenous genes and siRNA-mediated gene silencing, thus providing a powerful tool to functionally decipher genetic factors controlling adipogenesis and adipocyte functions.

© 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Keywords** CRISPRa; siRNA; Adipogenesis; Adipocyte; Browning; Gene expression

## 1. INTRODUCTION

Fat tissue biology has become of significant interest over the last decades due to its central role in energy homeostasis and obesity-related metabolic pathology. *In vitro* models of adipogenesis have been extensively studied due to the close resemblance between *in vitro* adipogenesis and fat cell differentiation *in vivo* [1]. Adipocytes are derived from mesenchymal stem cells (MSC) undergoing two distinct phases: commitment and terminal differentiation. Under specific environmental conditions, MSCs initiate adipogenic changes and become committed preadipocytes. *In vitro*, this commitment step can be induced by various hormonal stimuli such as the Bone Morphogenic Protein (BMP) and TGF $\beta$  family members, cell–cell contacts, or extra cellular matrix (ECM) composition and stiffness. The adipogenic

induction step from pre- to mature adipocyte can be triggered, at least in murine cells, by insulin, glucocorticoids, and Protein Kinase A (PKA) activation [2]. Mechanistically, the terminal differentiation is characterized by the induction of a complex transcriptional program where the transcription factor Peroxisome proliferator-activated receptor (PPAR)- $\gamma$ 2 is considered a “master regulator” [3]. Thus, *Pparγ2* expression is both necessary [4] and sufficient [5] to drive adipogenesis. Several other transcriptional factors are involved in the adipogenic process, including the CCAAT-enhancer-binding proteins (C/EBP) [2,6].

In contrast to classical white adipocytes, which primarily serve for energy storage, insulation, and adipokine secretion, brown and brite/beige adipocytes are capable of generating heat by bypassing the mitochondrial oxidative phosphorylation pathway through expression

Section of Integrative Physiology, Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

\*Corresponding author. University of Copenhagen, Faculty of Health and Medical Sciences, The Novo Nordisk Foundation Center for Basic Metabolic Research, Section on Integrative Physiology, Blegdamsvej 3, 07-7-48, DK-2200 N, Copenhagen, Denmark. E-mail: [emanuelli@sund.ku.dk](mailto:emanuelli@sund.ku.dk) (B. Emanuelli).

Received May 17, 2017 • Revision received June 28, 2017 • Accepted July 4, 2017 • Available online 8 July 2017

<http://dx.doi.org/10.1016/j.molmet.2017.07.001>

and activation of Uncoupling protein (UCP)-1, a process called non-shivering thermogenesis. PR domain Zink Finger Protein (PRDM)-16 has been shown not only to control the brown fat cell development [7], but also to drive the thermogenic program in white adipocytes both *in vivo* and *in vitro* [8,9]. Conversely, Zink Finger Protein (ZFP)-423, initially found to control preadipocyte determination by regulating *Ppar $\gamma$ 2* expression [10], was recently shown to suppress the thermogenic program, including *Ucp1* expression, in mature adipocytes [11]. Thus, the expression of key thermogenic genes such as *Ucp1* can be controlled, at least partially, by a potent regulatory-signaling driven by *Prdm16* or *Zfp423*. However, the complex processes involved in adipocyte commitment/maintenance, and particularly the synergistic effects of transcriptional regulators, are still poorly understood, calling for more accessible methods to manipulate gene expression in adipocytes. Manipulating gene expression in pre- and mature adipocytes is fundamental to the loss- and gain-of-function studies investigating the role of a given gene in regulating adipogenesis or adipocyte function. While gene silencing is generally easily achievable, several obstacles become obvious in the conventional overexpression approaches; these include the limiting size of the DNA construct and uncontrollable expression levels, which often result in non-physiological concentrations of the protein and thus affecting its physical properties. Additionally, manipulating gene expression in the mature adipocyte is challenging due to inefficient adenovirus-mediated gene expression [12] associated with cytopathogenicity [13] or poor gene silencing efficacy using transfection-based siRNA delivery as observed in e.g. 3T3-L1 cells [14]. Furthermore, since retroviral-based approaches depend on integration of the virus into the host genome, the likelihood of perturbing endogenous genes, and thus inducing protein signaling artifacts, must be taken into account. Although preadipocytes are more susceptible to gene manipulations compared to mature lipid-containing adipocytes, strategies targeting the preadipocyte to elucidate gene functions in the mature state should be avoided due to possible interference with the differentiation process *per se*. Several modern technical improvements indeed eased the manipulation of gene expression in adipocytes, including electroporation [14], reverse transfection [15], various viral-based vector delivery systems [16] and a stable expression of the Coxsackievirus and adenovirus receptor (CAR) [17], however, efficient and easily adaptable tools allowing for sustainable overexpression and bi-directional gene manipulation in mature fat cells are still largely limited.

The versatile gene-editing system CRISPR-Cas9, first used to edit the mammalian genome [18,19], has several derived applications including repressing (CRISPRi) or activating (CRISPRa) endogenous genes [20]. Subtypes of the activator system rely on the enzymatically dead Cas9 enzyme coupled to a transactional activator — often the VP64 domain. An introduction of a single guide (sg) RNA targeting a specific promoter allows for manifold induction of an endogenous gene and, importantly, co-expression of multiple sgRNAs allows multiplex gene expression [21]. Recently, more advanced and potent versions of the CRISPRa systems have been engineered such as the Synergistic Activation Mediator (SAM) system, in which a third component consisting of the P65 subunit of the transcription factor NF- $\kappa$ B and the activator domain found on heat-shock factor 1 form a complex with the dCAS9-sgRNA to synergistically boost the transcription [21], making it one of the most powerful CRISPRa types developed thus far [22].

We hypothesized that the CRISPRa SAM system can be adopted as a tool for (co-)activation of key functional genes in preadipocytes, as well as for manipulation of gene expression in mature adipocytes.

We showed that endogenous *Ppar $\gamma$ 2*-expression can be induced to varying levels, depending on sgRNA-promoter region binding position;

importantly this expression was sufficient to promote adipogenesis and thus functionally affect cell morphology. Furthermore, we demonstrated that co-delivery of sgRNAs controlling the expression of either *Prdm16* or *Zfp423*, in combination with a *Ppar $\gamma$ 2*-targeting sgRNA, influenced the differentiation towards either a more brite/beige or white phenotype, respectively. Lastly, we showed that CRISPRa SAM permitted the manifold induction of endogenous genes, here *Ucp1*, in mature adipocytes. This overexpression was successfully combined with siRNA-mediated gene silencing for other targets, thereby demonstrating efficient bidirectional manipulation of gene expression in mature fat cells after bypassing the differentiation period.

Thus, we report here a detailed *in vitro* protocol using easily accessible tools to manipulate gene expression in adipocytes. The major advantage of this model is that once the core components of the CRISPRa SAM system are established, it is easy to use and allows concurrent expression and silencing of virtually any gene of interest — either alone or in combination — in both pre- and mature adipocytes.

## 2. MATERIALS AND METHODS

### 2.1. Reagents

C3H/10T1/2 clone 8 cells were obtained from ATCC (Wesel, Germany). Lenti dCas9-VP64 vector (#61425), lenti MS2-P65-HSF vector (#61426) and sgRNA cloning backbone (#61424) were from Addgene (Cambridge, MA, USA). Glutamine, Hygromycin, Blasticidin, 3-Isobutyl-1-methylxanthine (IBMX), human insulin, Rosiglitazone, Dexamethasone, CL 316,243, and siRNA (Mission<sup>®</sup>; SASI\_Mm01\_00036294) were purchased from Sigma Aldrich (Brøndby, Denmark); BODIPY, DMEM-high glucose, Penicillin-streptomycin, Sodium Pyruvate, Non-essential amino acids, Lipofectamine 3000 reagent, Lipofectamine RNAiMAX, DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) AlexaFluor 594 antibody, and ProLong Gold Antifade reagent were from Thermo Fisher Scientific (Slangerup, Denmark); BMP2 was from R&D Systems (Abingdon, UK); Mirus TransIT-X2 was from Kem-En-Tec (Taastrup, Denmark); anti-mouse UCP1 antibody Cat#UCP11-A (AH Diagnostics, Aarhus, Denmark); FCCP, Rotenone, Antimycin A, and XF assay medium modified DMEM were from Agilent Technologies (Copenhagen, Denmark); oligo DNAs from TagCopenhagen (Copenhagen, Denmark); Superfect was from Qiagen (Copenhagen, Denmark), and Lenti-X concentrator was from Clontech (Saint-Germain-en-Laye, France). iScript was from BIO-RAD (Copenhagen, Denmark); RNeasy was from Qiagen (Copenhagen, Denmark); Brilliant III SYBR green Master Mix was from AH Diagnostics.

### 2.2. Generation of the C3H/10T1/2-CRISPRa-SAM stable cell line

Lentiviruses expressing dCas9-VP64 and MS2-P65-HSF1 were generated in 293 cells by co-transfection of the packaging plasmids psPAX.2 and psMD2.g using Superfect transfection reagent. Virus-containing supernatant was harvested 72 h post transfection and concentrated using Lenti-X concentrator. Sub-confluent C3H/10T1/2 cells were subsequently exposed to virus (with polybrene; 8  $\mu$ g/ml) and selected with blasticidin (2.5  $\mu$ g/ml) and hygromycin (200  $\mu$ g/ml). Expression of the two components was verified using RT-qPCR. The resulting cell-line stably expressing the SAM components was termed “C3H/10T1/2-CRISPRa-SAM”.

### 2.3. Single guide (sg)RNA design and cloning

sgRNAs were designed using the online tool: <http://sam.genome-engineering.org/database/> and cloned into the backbone vector according to Konermann et al. [21]. Correct insertion was verified by sequencing. sgRNA sequences: Prdm16; GCGGCGGCGGCGGCGAAG,

Zfp423; GAGGAGGGTGAGGGTGGCGG, *Ucp1*; GGGAGTGACGCGCGG CTGGG. Ppar $\gamma$ 2 sgRNAs are listed in Figure 1A.

#### 2.4. Transfection of pre- and mature adipocytes

45,000 C3H/10T1/2-CRISPRa-SAM cells were seeded in 12-wells and transfected with 250 ng of sgRNA per well using TransIT-X2 reagent. Evaluation of sgRNA efficacy was done 48 h post transfection. 2,000–4,000 C3H/10T1/2-CRISPRa-SAM cells were seeded in the seahorse-wells and transfected with 40 ng of sgRNA per well using TransIT-X2 reagent. For transfection of mature adipocytes, 500,000 cells were reverse transfected with 2  $\mu$ g of sgRNA using TransIT-X2, Lipofectamine-3000 or RNAiMAX reagent. For bidirectional expression studies, a final concentration of 50 nM siRNA targeting the pyruvate kinase M [23] was added. Supplemental Figure 1 summarizes optimal details for transfection of pre- and mature adipocytes with sgRNA and siRNA allowing bidirectional manipulation of gene expression.

#### 2.5. Cell culture and differentiation

C3H/10T1/2-CRISPRa-SAM cells were cultured in DMEM high glucose with 10% fetal bovine serum, 1% Penicillin and Streptomycin, Blasticidin, and Hygromycin. For differentiation of C3H/10T1/2-CRISPRa-SAM cells with Ppar $\gamma$ 2 sgRNA, cells were given Rosiglitazone (5  $\mu$ M) every other day starting 2 days after transfection. For co-expression studies Rosiglitazone (5  $\mu$ M) was only added for 48 h following transfection. For transfection of mature adipocytes, C3H/10T1/2-CRISPRa-SAM cells were pre-treated with BMP2 (100 ng/ml) for four days, and differentiation was induced at confluence by Dexamethasone (5  $\mu$ M), IBMX (500  $\mu$ M), insulin (0.85  $\mu$ M), and Rosiglitazone (1  $\mu$ M) for two days followed by insulin (0.85  $\mu$ M) and Rosiglitazone (1  $\mu$ M) for another two days; at this point, the differentiated cells were

ready for reverse transfection. Differentiated cells were kept in complete media (DMEM, 12% FBS, 1% Penicillin and Streptomycin, 1% extra Glutamine, 1% non-essential amino acids, 1% Sodium Pyruvate). For BODIPY/DAPI staining of pre- and mature adipocytes, BODIPY (0.1  $\mu$ g/ml) and DAPI (0.5  $\mu$ g/ml) were diluted in DMEM without serum and incubated for 30 min.

#### 2.6. Quantitative PCR


RNA was extracted using RNeasy and cDNA synthesized using the iScript kit according to the manufacturer's instructions. Real-time PCR was performed using the CFX384 Real-Time System according to the supplier's manual (Bio-Rad). Each cDNA sample was run in duplicates and raw data were normalized to house keeping genes (*18S* or *Tbp*). Primer sequences are described in Supplemental Table 1.

#### 2.7. Oxygen consumption

Real-time measurements of oxygen consumption rates (OCR) were performed using a Seahorse XF96 Extracellular Flux Analyzer (Agilent Technologies). The cell culture medium was changed 1 h before the first measurement to XF assay medium modified DMEM (Agilent Technologies) supplemented with 5 mM glucose and 2 mM L-glutamine and adjusted to pH 7.4. OCR was measured under basal conditions and after injection of 5  $\mu$ M CL 316,243, 1  $\mu$ M FCCP and 1  $\mu$ M Rotenone combined with 1  $\mu$ M Antimycin A. Area under the curve (AUC) was calculated from the time of the CL 316,243 injection (uncoupling) or the FCCP injection (maximal respiratory capacity).

#### 2.8. Flow cytometry

Adipocytes were stained with BODIPY and DAPI for 30 min before trypsinization and resuspended in PBS + 1% BSA. Cells were forced



**Figure 1: Regulating endogenous Ppar $\gamma$ 2 expression and adipogenesis.** (A) Ppar $\gamma$ 2 sgRNA sequences, distance to transcription start site (TSS) and fold induction. (B) Fold induction of Ppar $\gamma$ 2 expression two days post transfection in the C3H/10T1/2-CRISPRa-SAM cells using different sgRNAs binding distinct places on the Ppar $\gamma$ 2 promoter. Differentiation of C3H/10T1/2-CRISPRa-SAM cells using Ppar $\gamma$ 2 sgRNA or empty vector (EV) stimulated with 5  $\mu$ M Rosiglitazone or vehicle (DMSO) for 8 days assessed by (C) BODIPY (green) and DAPI (blue) staining or (D) RT-qPCR of the adipogenic markers *Ap2* and *Adiponectin* and *Pparγ2*. Data are presented as means + SEM, n = 3, One-way ANOVA with Dunnett's test, \*p < 0.05 versus EV transfected cells (B) or versus the Ppar $\gamma$ 2 sgRNA transfected cells treated with Rosiglitazone (D).



through a cell-strainer and gated according to BODIPY intensity on a BD FACS Aria III sorter.

### 2.9. Immunocytochemistry

After trypsinization, cells were reseeded during the reverse transfection on gelatin-coated coverslips. Two days post-transfection, cells were fixed in 4% paraformaldehyde, permeabilized (0.1% Triton-X in PBS), and blocked (1% FBS in PBS) prior to primary antibody (1:400) incubation overnight in a humidified chamber at 4 °C. UCP1 protein was visualized using a secondary AlexaFluor 594 antibody (1:1000) for 1 h at room temperature. Cells were counter-stained with BODIPY for 30 min at room temperature and DAPI (300 nM in PBS) for 10 min at room temperature for lipid and nuclear detection, respectively. Coverslips were mounted on glass slides with ProLong Gold Antifade. Imaging was performed using a confocal microscope (Zeiss LSM 780) with  $\times 20$  water-immersion or  $\times 63$  oil-immersion lenses; images were captured in Z-stacks (16–24 stacks per image; ZEN Black software) using identical exposure settings throughout conditions for qualitative comparisons.

### 2.10. Statistical analyses

All data are presented as means + SEM. Comparisons between groups were carried out by ANOVA followed by Dunnett-corrected or Sidak-corrected multiple comparisons or Bonferroni-corrected Student's *t*-test using Prism (GraphPad). P-values below 0.05 were considered significant.

## 3. RESULTS

To increase the expression of endogenous genes in pre- and mature adipocytes, we first established a C3H/10T1/2 MSC line stably expressing the two core components of the SAM system (Supplemental Figure 2); the cell-line is here after referred to as “C3H/10T1/2-CRISPRa-SAM”.

### 3.1. CRISPRa-mediated overexpression of the endogenous *Pparγ2* gene promotes adipocyte differentiation

In an attempt to create a model of *in vitro* adipogenesis without the use of any differentiation cocktail, we assessed the ability of the CRISPRa SAM system to induce adipocyte differentiation by targeted transcription of endogenous *Pparγ2* alone. Indeed PPAR $\gamma$ 2 is considered a master transcription factor driving adipogenesis. In fact, ectopic overexpression and stimulation of PPAR $\gamma$ 2 alone promotes adipogenesis [5]. We thus designed 5 different sgRNAs targeting different regions of the *Pparγ2* promoter and tested their efficacy in inducing *Pparγ2* expression (Figure 1A and B). We observed varying degrees of induction ranging from  $\sim 200$  fold (sgRNA#1) to more than 12,000 fold (sgRNA#2). A pool of all 5 sgRNAs simultaneously targeting the *Pparγ2* promoter did not exceed the over-expression level reached with sgRNA#2 alone, indicating no additive effect. Substantial differentiation was achieved in C3H/10T1/2-CRISPRa-SAM cells transfected with sgRNA#2 and treated with the PPAR $\gamma$ 2 agonist Rosiglitazone, as measured by BODIPY-staining (Figure 1C) and expression levels of classic adipogenic markers such as *Adipocyte protein (Ap)-2* and *AdipoQ* (Figure 1D). These data show that CRISPRa SAM is effective in controlling the expression level of endogenous genes in preadipocytes, consequently affecting cell fate — here adipogenesis.

### 3.2. Multiplex gene induction influences the characteristics of mature adipocytes


Next, we investigated whether the CRISPRa SAM system could be used to promote or repress “brite/beige-like” characteristics by

simultaneously targeting specific endogenous genes. As a proof of principle, we chose the brown-promoting factor *Prdm16* [9] and the white-maintaining factor *Zfp423* [11], which were previously shown to either increase or suppress the expression of thermogenic genes in adipocytes, respectively. We tested the efficacy of 5 sgRNAs for both *Prdm16* and *Zfp423* and selected the most potent guides for further studies (data not shown). We transfected cells with sgRNAs for these two factors either alone or in combination with the *Pparγ2* sgRNA#2. In contrast to the “standard” differentiation cocktail containing Dexamethasone, IBMX and insulin (DMI), we induced adipogenesis by Rosiglitazone alone specifically targeting successfully transfected cells to differentiate. Thus, this system allows direct interrogation of the effects of gene multiplexing within the same cell.

As shown in Figure 2A–C, the sgRNAs produced a robust induction of *Pparγ2* ( $\sim 4000$  fold), *Prdm16* ( $\sim 275$  fold) and a mild but significant up-regulation of *Zfp423* ( $\sim 4$  fold) compared to empty vector (EV) controls in preadipocytes 2 days post transfection. Interestingly, we observed that the basal expression levels of both *Pparγ2* and *Prdm16* were manifold lower than that of *Zfp423* in the C3H/10T1/2-CRISPRa-SAM cells, suggesting an inverse correlation between basal expression level and sgRNA efficacy. Activation of *Prdm16* or *Zfp423* did not affect overall differentiation levels in *Pparγ2*-transfected cells, as assessed by *Ap2* and *AdipoQ* expression (Figure 2D and E). However, when differentiated cells were stimulated with the  $\beta$ 3 adrenergic receptor agonist CL 316,243 (CL), induction of *Ucp1* was significantly potentiated by co-activation of *Prdm16* compared to *Pparγ2* alone, and in contrast to *Zfp423* co-expression, which blocked *Ucp1* up-regulation (Figure 2F). A similar trend was observed for *Cidea* (Figure 2G). In line with these data, co-activation of *Prdm16* with *Pparγ2* showed increased CL-induced uncoupling and maximal respiratory capacity compared to co-activation of *Zfp423* and *Pparγ2* (Figure 2H). Thus, we demonstrated that CRISPRa SAM is suitable to be used for multiplex gene expression, and thereby for the control of thermogenic gene expression and mitochondrial respiration in adipocytes, independently of differentiation.

### 3.3. Regulating endogenous gene expression in mature adipocytes

Next, we aimed at utilizing CRISPRa SAM to increase gene expression in mature adipocytes. To bypass the differentiation state, we modified previous siRNA-based transfection protocols for mature adipocytes [15,23]. Briefly, this method utilizes reverse transfection (transfection of cells in suspension) with siRNAs in adipocyte cell-lines 6–9 days after induction and has proven highly efficient for gene silencing. We substituted the siRNAs with sgRNAs and employed a sgRNA-expressing plasmid targeting the *Ucp1* promoter. Additionally, we tested three different transfection reagents (Lipofectamine3000, TransIT and RNAiMAX) for their efficiency to deliver the sgRNAs. Adipocytes were reverse transfected 8 days after differentiation start, followed by gene expression and immunocytochemical analyses two days post-transfection. Importantly, to demonstrate that the *Ucp1* induction indeed occurred in mature cell population, we stained cells with BODIPY to collect low BODIPY-fluorescence cells (non-adipocytes) and high BODIPY-fluorescence cells (adipocytes) by fluorescence-activated cell sorting (FACS). Preadipocytes were almost exclusively found in the group of cells with “low” BODIPY-fluorescence intensity (Figure 3A), whereas the majority of the differentiated cells appeared in the “high” BODIPY-fluorescence intensity group (Figure 3B). Importantly, reverse transfection of the *Ucp1* sgRNA led to a robust induction of *Ucp1* (more than  $4 \times 10^3$  fold for TransIT reagent), regardless of transfection reagent in the mature adipocytes population (Figure 3C). Lastly, using immunofluorescence against UCP1 protein, we confirmed



**Figure 2: Co-expression of either *Prdm16* or *Zfp423* with *Pparγ2* regulates thermogenic characteristics in adipocytes.** C3H/10T1/2-CRISPRa-SAM cells were transfected with EV, *Pparγ2* and/or *Prdm16*/*Zfp423* sgRNAs. Expression of (A) *Pparγ2*, (B) *Prdm16*, (C) *Zfp423*, (D) *Ap2*, and (E) *AdipoQ* were assessed by RT-qPCR. To stimulate the expression of thermogenic genes, C3H/10T1/2-CRISPRa-SAM cells were treated with 5  $\mu$ M CL 316,243 for 6 h and (F) *Ucp1* and (G) *Cidea* expression assessed by RT-qPCR. Oxygen consumption was assessed using Seahorse (H). Data are presented as means + SEM,  $n = 4$  ( $n = 3$  for Seahorse data), ANOVA with Dunnett's (A–E) or Sidak-corrected test (H) or Bonferroni-corrected Student's *t*-tests (F + G), \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  versus the *Pparγ2* sgRNA transfected cells.

that reverse transfection of the *Ucp1*-sgRNA indeed leads to up-regulation of UCP1 protein levels in mature adipocytes, with UCP1 immunoreactivity predominantly detected in lipid-laden BODIPY-positive cells transfected with *Ucp1* sgRNA (Figure 3D, Supplemental Videos 1A+B). Hence, CRISPRa SAM is appropriate for endogenous RNA and protein overexpression in mature adipocytes. Of note, delivering sgRNAs as U6-expression cassettes [24], thereby reducing the size from  $\sim 3$  kb to just  $\sim 430$  bp, resulted in the induction of *Ucp1* expression, although the efficacy was lower compared to the plasmid-based delivery (Supplemental Figure 3).

Supplementary videos related to this article can be found online at <http://dx.doi.org/10.1016/j.molmet.2017.07.001>.

### 3.4. Bidirectional gene regulation in mature adipocytes


Almost any change in cell homeostasis is a net result of changes in numerous genes being either induced or repressed. Therefore, we tested whether the CRISPRa SAM system could be used in combination with gene silencing using siRNA in mature adipocytes. As an example, we used the *Ucp1* sgRNA in combination with siRNAs targeting pyruvate kinase M (*Pkm*), which we have previously shown to be efficient in mature adipocytes [23]. We also tested the efficacy of the three transfection reagents described in Figure 3 to efficiently deliver both sgRNAs and siRNAs in mature cells. As shown in Figure 4A, *Ucp1* expression was robustly and equally induced following transfection of its sgRNA using any of the transfection reagents. However, the level of *Pkm* knockdown was dependent on the transfection reagent. Indeed, 89% and 83% knockdown of *Pkm* were obtained with TransIT and RNAiMAX, respectively, when combined with *Ucp1* overexpression, whereas Lipofectamine 3000 produced a 49% reduction. These data

demonstrate that bidirectional gene expression can be achieved by combining the CRISPRa SAM system with siRNAs in the same transfection when a compatible transfection reagent is used.

## 4. DISCUSSION

Genetic loss- and gain-of-function studies are invaluable to elucidate the function of genes and proteins. Gene silencing using RNAi revolutionized loss-of-function studies and has been extensively used to study adipocyte biology [14,25]. However, gene overexpression has remained a challenge, especially in mature adipocytes, due to poor plasmid delivery and time-consuming experimental procedures such as subcloning and virus production. Other pitfalls such as gene size limitations and lack of control over the ectopic expression level further complicate the feasibility of overexpression studies.

While CRISPRa has some drawbacks including limited activation of genes with high baseline expression [21,22], and possible sgRNAs off-targets similar to RNAi-based strategies relying on complementary nucleotides should not be ignored, a number of advantages greatly favor this technique. Indeed, we show here that CRISPRa SAM allows for overexpression of endogenous genes for which the level of overexpression can be controlled by selecting appropriate sgRNAs of various efficacies. Importantly, we also demonstrated that CRISPRa SAM can be applied in mature adipocytes, thus overcoming many caveats of the existing conventional overexpression tools. It is of interest that different levels of expression can be achieved by selecting different sgRNAs (e.g. *Pparγ2* from  $\sim 200$ -fold to  $\sim 12,000$ -fold compared to EV controls); as this allows to adjust the induction of a given gene of interest to mirror a physiological or pathological situation.



**Figure 3: Induction of *Ucp1* mRNA and protein in mature adipocytes.** C3H/10T1/2-CRISPRa-SAM cells were differentiated to mature adipocytes and reverse transfected with *Ucp1* sgRNA or EV. Cell sorting was used to select mature adipocytes. (A) Preadipocytes stained with BODIPY elicited a “low” BODIPY-fluorescence intensity compared to (B) mature adipocytes. (C) After reverse transfection the mature adipocyte fraction was collected and endogenous *Ucp1* expression examined by RT-qPCR. (D) Mature adipocytes, reverse-transfected with either EV or *Ucp1* sgRNA, were fixed and stained for UCP1 protein expression (red), nuclei (blue) and lipids (green) using immunofluorescence and BODIPY/DAPI staining. 20× and 63× magnifications are shown. n = 3–4, Bonferroni-corrected Student’s *t*-test, \*\**p* < 0.01 versus EV transfected cells.


Furthermore, endogenous promoters frequently control several isoforms of the same gene, including intronic microRNAs [26]. Thus, the CRISPRa should allow the induction of all promoter-based products, mimicking the activation of a biological pathway to a largely better extent compared to ectopic overexpression of an isoform of interest. Here, not only did we prove that CRISPRa SAM is a useful tool to overexpress genes in adipocyte cell-lines, we also provided a model of controlling brite/beige-like characteristics such as induction of *Ucp1* expression and increased mitochondrial respiration. To study key adipogenic genes, we chose the C3H/10T1/2 cells, which were established in 1972 from clone 8 derived from mouse embryo cells [27]. This is an MSC cell line with the potential to differentiate into both myofibers [28] and adipocytes with either white or brown characteristics e.g. through treatment with the BMP cytokines such as BMP2, -4 or -7 [29–31]; however, any adipocyte cell-line may be engineered to express the two CRISPRa SAM components. Based on the work by Tontonoz, Hu, and Spiegelman [5], in which they elegantly demonstrated that retroviral delivery of *Pparg2* was sufficient to drive adipogenesis in NIH 3T3 cells, we reproduced this finding through overexpression of the endogenous *Pparg2* gene. Furthermore, by manipulating the endogenous expression of either *Prdm16* [9] or *Zfp423* [10], we provide an accessible, easy, and quick system for manipulating brite/beige-like characteristics without exogenous gene delivery, hence yielding higher physiological relevance. Indeed, the robust induction of *Prdm16* potentiated the effect of CL-treatment on both *Ucp1* and *Cidea* expression, whereas *Zfp423* overexpression repressed it.

Interestingly, PRDM16 was recently shown to drive *Ucp1* expression through binding to the subunit MED-1 of the Mediator complex at the

2.5 kb upstream enhancer [32]. Whether a similar mechanism lies behind the induction of *Cidea* is currently not known. Gupta et al. [10] also showed that similarly to *Prdm16* [7], ectopic expression of *Zfp423* drives *Pparg2* expression. We observed a similar trend (Figure 2A); however, this was not sufficient to induce differentiation in this cell line as measured by *Ap2* and *AdipoQ* expression.

Of note, ectopic expression of MyoD1 in C3H/10T1/2 cells has been shown to drive myogenesis [33]. Thus, similarly to this *Pparg2*-driven adipogenic commitment model, overexpression of MyoD1, and/or (co-) expression of novel myogenic players in C3H/10T1/2-CRISPRa-SAM cells may provide a suitable model to assess whether a given target affects myogenic processes in this cell line.

The multiplex feature of CRISPRa allows better interrogation of novel gene/protein targets and high throughput-based data, including commonly used OMICs-based discoveries to predict key pathways regulated in a given physiological or pathological condition of interest. The majority of validation/follow-up studies seek causation by addressing the action of one selected target, either through overexpression and/or knockdown; however, this may be too simplistic — as illustrated by the necessity of co-ectopic expression of PPAR $\gamma$ /RXR $\alpha$  with PRDM16 to uncover the full transcriptional capacity of PRDM16 [7]. In stark contrast to the standard single gene-targeted approach, our method grants synergistic and bidirectional gene expression in both pre- and mature adipocytes allowing for more sophisticated experimental designs to study complex multi-player signaling pathways such as adipogenesis, in which a multitude of genes is regulated for the process to occur [34]. Complementing a modified CRISPRa approach to allow gene activation and gene knockout simultaneously [35], our method is the first to combine CRISPRa with siRNA, thereby allowing



**Figure 4: Bidirectional gene regulation in mature adipocytes.** C3H/10T1/2-CRISPRa-SAM cells were differentiated to mature adipocytes and reverse transfected with a combination of *Ucp1* sgRNA, EV sgRNA, *Pkm* siRNA, or a negative control siRNA. Expression of (A) *Ucp1* and (B) *Pkm* were measured by RT-qPCR. Data are presented as means + SEM, n = 3, one-way ANOVA with Dunnett's test, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 versus EV transfected cells with same transfection reagent.

easy to use, efficient, and reversible gene manipulation without altering the genome. Employing the simultaneous and bi-directional gene expression manipulation tool we described here, therefore, can serve as a powerful resource for assessing the role of key target genes involved in the regulation of adipocyte cell fate and function.

## 5. CONCLUSION

We report a methodological advancement using a combination of simple and robust tools to selectively increase the expression of endogenous genes in both pre- and mature adipocytes. We propose it to be used not only as an alternative method to current gain-of-function studies *in vitro*, but also as a new method for studying bidirectional gene expression. From a therapeutic standpoint, the CRISPRa system also yields a high potential for clinical applications since it does not require changes in the host genome.

## FUNDING SOURCES

ML was a recipient of a research grant from the Danish Council for Independent Research and Sapere Aude Research Talent: DFF — 5053-00112. KP, MSI, PSSP and BE were supported by Novo Nordisk Foundation. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (<http://www.metabol.ku.dk>).

## AUTHOR CONTRIBUTIONS

ML and BE conceived and designed the study; ML wrote the manuscript with input from KP and BE. ML, KP, and MSI carried out the main experimental work and interpreted the results. PSSP provided

technical assistance throughout the study. BE supervised the work. All authors approved the final version of the manuscript.

## RESOURCE SHARING

The C3H/10T1/2-CRISPRa-SAM cell line and sgRNA-containing plasmids are available upon request.

## ACKNOWLEDGEMENTS

We would like to thank Dr. Zach Gerhart-Hines for his scientific input. We acknowledge the Flow Cytometry Core Facility, University of Copenhagen, for cell sorting and the Core Facility for Integrated Microscopy, University of Copenhagen, for assisting with confocal imaging.

## CONFLICT OF INTEREST

The authors declare no competing financial interests.

## APPENDIX A. SUPPLEMENTARY DATA

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.molmet.2017.07.001>.

## REFERENCES

- [1] Rosen, E.D., Spiegelman, B.M., 2000. Molecular regulation of adipogenesis. *Annual Review of Cell and Developmental Biology* 16:145–171.
- [2] Cristancho, A.G., Lazar, M.A., 2011. Forming functional fat: a growing understanding of adipocyte differentiation. *Nature Reviews Molecular Cell Biology* 12:722–734.



- [3] Tontonoz, P., Spiegelman, B.M., 2008. Fat and beyond: the diverse biology of PPARgamma. *Annual Review of Biochemistry* 77:289–312.
- [4] Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., et al., 1999. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. *Molecular Cell* 4:597–609.
- [5] Tontonoz, P., Hu, E., Spiegelman, B.M., 1994. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. *Cell* 79: 1147–1156.
- [6] Lefterova, M.I., Haakonsson, A.K., Lazar, M.A., Mandrup, S., 2014. PPAR-gamma and the global map of adipogenesis and beyond. *Trends in Endocrinology and Metabolism* 25:293–302.
- [7] Seale, P., Bjork, B., Yang, W., Kajimura, S., Chin, S., Kuang, S., et al., 2008. PRDM16 controls a brown fat/skeletal muscle switch. *Nature* 454:961–967.
- [8] Seale, P., Conroe, H.M., Estall, J., Kajimura, S., Frontini, A., Ishibashi, J., et al., 2011. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. *Journal of Clinical Investigation* 121:96–105.
- [9] Seale, P., Kajimura, S., Yang, W., Chin, S., Rohas, L.M., Uldry, M., et al., 2007. Transcriptional control of brown fat determination by PRDM16. *Cell Metabolism* 6:38–54.
- [10] Gupta, R.K., Arany, Z., Seale, P., Mepani, R.J., Ye, L., Conroe, H.M., et al., 2010. Transcriptional control of preadipocyte determination by Zfp423. *Nature* 464:619–623.
- [11] Shao, M., Ishibashi, J., Kusminski, C.M., Wang, Q.A., Hepler, C., Vishvanath, L., et al., 2016. Zfp423 maintains white adipocyte identity through suppression of the beige cell thermogenic gene program. *Cell Metabolism* 23: 1167–1184.
- [12] Orlicky, D.J., Schaack, J., 2001. Adenovirus transduction of 3T3-L1 cells. *The Journal of Lipid Research* 42:460–466.
- [13] Carlotti, F., Bazuine, M., Kekarainen, T., Seppen, J., Pognonec, P., Maassen, J.A., et al., 2004. Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 adipocytes. *Molecular Therapy* 9:209–217.
- [14] Jiang, Z.Y., Zhou, Q.L., Coleman, K.A., Chouinard, M., Boese, Q., Czech, M.P., 2003. Insulin signaling through Akt/protein kinase B analyzed by small interfering RNA-mediated gene silencing. *Proceedings of the National Academy of Sciences of the United States of America* 100:7569–7574.
- [15] Kilroy, G., Burk, D.H., Floyd, Z.E., 2009. High efficiency lipid-based siRNA transfection of adipocytes in suspension. *PLoS One* 4:e6940.
- [16] Gomez-Banoy, N., Lo, J.C., 2017. Genetic manipulation with viral vectors to assess metabolism and adipose tissue function. *Methods in Molecular Biology* 1566:109–124.
- [17] Ross, S.A., Song, X., Burney, M.W., Kasai, Y., Orlicky, D.J., 2003. Efficient adenovirus transduction of 3T3-L1 adipocytes stably expressing coxsackie-adenovirus receptor. *Biochemical and Biophysical Research Communications* 302:354–358.
- [18] Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., et al., 2013. Multiplex genome engineering using CRISPR/Cas systems. *Science* 339: 819–823.
- [19] Mali, P., Yang, L., Esvelt, K.M., Aach, J., Guell, M., DiCarlo, J.E., et al., 2013. RNA-guided human genome engineering via Cas9. *Science* 339:823–826.
- [20] Gilbert, L.A., Horlbeck, M.A., Adamson, B., Villalta, J.E., Chen, Y., Whitehead, E.H., et al., 2014. Genome-scale CRISPR-mediated control of gene repression and activation. *Cell* 159:647–661.
- [21] Konermann, S., Brigham, M.D., Trevino, A.E., Joung, J., Abudayyeh, O.O., Barceña, C., et al., 2015. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. *Nature* 517:583–588.
- [22] Chavez, A., Tuttle, M., Pruitt, B.W., Ewen-Campen, B., Chari, R., Ter-Ovanesyan, D., et al., 2016. Comparison of Cas9 activators in multiple species. *Nature Methods* 13:563–567.
- [23] Isidor, M.S., Winther, S., Basse, A.L., Petersen, M.C., Cannon, B., Nedergaard, J., et al., 2016. An siRNA-based method for efficient silencing of gene expression in mature brown adipocytes. *Adipocyte* 5:175–185.
- [24] Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., Zhang, F., 2013. Genome engineering using the CRISPR-Cas9 system. *Nature Protocols* 8: 2281–2308.
- [25] Zhou, Q.L., Park, J.G., Jiang, Z.Y., Holik, J.J., Mitra, P., Semiz, S., et al., 2004. Analysis of insulin signalling by RNAi-based gene silencing. *Biochemical Society Transactions* 32:817–821.
- [26] Ruby, J.G., Jan, C.H., Bartel, D.P., 2007. Intronic microRNA precursors that bypass Drosha processing. *Nature* 448:83–86.
- [27] Reznikoff, C.A., Brankow, D.W., Heidelberger, C., 1973. Establishment and characterization of a cloned line of C3H mouse embryo cells sensitive to postconfluence inhibition of division. *Cancer Research* 33:3231–3238.
- [28] Pinney, D.F., Emerson Jr., C.P., 1989. 10T1/2 cells: an in vitro model for molecular genetic analysis of mesodermal determination and differentiation. *Environmental Health Perspectives* 80:221–227.
- [29] Huang, H., Song, T.J., Li, X., Hu, L., He, Q., Liu, M., et al., 2009. BMP signaling pathway is required for commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. *Proceedings of the National Academy of Sciences of the United States of America* 106:12670–12675.
- [30] Tseng, Y.H., Kokkotou, E., Schulz, T.J., Huang, T.L., Winnay, J.N., Taniguchi, C.M., et al., 2008. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. *Nature* 454:1000–1004.
- [31] Xue, R., Wan, Y., Zhang, S., Zhang, Q., Ye, H., Li, Y., 2014. Role of bone morphogenetic protein 4 in the differentiation of brown fat-like adipocytes. *American Journal of Physiology - Endocrinology and Metabolism* 306: E363–E372.
- [32] Iida, S., Chen, W., Nakadai, T., Ohkuma, Y., Roeder, R.G., 2015. PRDM16 enhances nuclear receptor-dependent transcription of the brown fat-specific Ucp1 gene through interactions with Mediator subunit MED1. *Genes & Development* 29:308–321.
- [33] Tapscott, S.J., Davis, R.L., Thayer, M.J., Cheng, P.F., Weintraub, H., Lassar, A.B., 1988. MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. *Science* 242:405–411.
- [34] Jang, M.K., Lee, S., Jung, M.H., 2016. RNA-seq analysis reveals a negative role of KLF16 in adipogenesis. *PLoS One* 11:e0162238.
- [35] Dahlman, J.E., Abudayyeh, O.O., Joung, J., Gootenberg, J.S., Zhang, F., Konermann, S., 2015. Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease. *Nature Biotechnology* 33:1159–1161.